This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Radiologic Imaging  • Renal Diseases  • Renal Diseases, Other  • Magnetic Resonance Imaging  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2007;297:252-253.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Contrast agents used in magnetic resonance imaging (MRI) studies for patients with renal insufficiency are associated with increased mortality in some cases, according to new findings by researchers.

Speaking at the annual Scientific Assembly of the Radiological Society of North America held here in November, Emanuel Kanal, MD, director of Magnetic Resonance Services and a professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, alerted colleagues to the emergence of nephrogenic systemic fibrosis (NSF) and its association with gadolinium-based contrast agents.

In nephrogenic systemic fibrosis, a rare condition only seen in patients with kidney disease, thickening skin can inhibit joint movement. In some cases, the disorder can increase mortality risk from comorbid conditions. (Photo credit: Arch Dermatol. 2003;139:903-906)

"The number of professionals who have heard of, let alone made a diagnostic stab at, NSF is a tiny drop in the bucket in the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?